This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Efstratiadis, G. Articles by Manes, C. Search for Related Content PubMed PubMed Citation Articles by Efstratiadis, G. Articles by Manes, C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Metabolic Syndrome Social Bookmarking                   What's this?

Total Serum Insulin-like Growth Factor-1 and C-Reactive Protein in Metabolic Syndrome With or Without Diabetes

Department of Nephrology, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece, efstrati{at}med.auth.gr

Georgios Tsiaousis, MD

Diabetes Unit, Papageorgiou General Hospital, Thessaloniki, Greece

Vasilios G. Athyros, MD, FASA, FACS

Atherosclerosis and Metabolic Syndrome Units, 2nd Prop. Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece

Despina Karagianni, MD

Diabetes Unit, Papageorgiou General Hospital, Thessaloniki, Greece

Aikaterini Pavlitou-Tsiontsi, MD

Department of Immunology, Papageorgiou General Hospital, Thessaloniki, Greece

Anastasia Giannakou-Darda, MD

Department of Immunology, Papageorgiou General Hospital, Thessaloniki, Greece

Christos Manes, MD

Diabetes Unit, Papageorgiou General Hospital, Thessaloniki, Greece

There are only a few data on the relationship of insulin-like growth factor-1 (IGF-1), implicated in glucose homeostasis, and C-reactive protein (CRP), a measure of subclinical systemic inflammation, in patients with the metabolic syndrome (MetS). The authors investigated, in a cross-sectional design, the correlation between total IGF-1 and CRP in 170 subjects. Among them 123 had the MetS (National Cholesterol Program ATP III definition) and 47 did not, and 136 had type 2 diabetes mellitus (DM) and 34 did not. Anthropometric variables, clinical characteristics, as well as laboratory measurements, including total IGF-1 and CRP, were recorded. CRP levels showed a significant negative correlation with total IGF-1 concentrations, both in the whole study population (r = -0.252, p=0.001) and the MetS group (r = -0.203, p=0.025), regardless of the presence of DM. This correlation remained significant after adjusting for age, gender, smoking status, and waist circumference (r = -0.18, p=0.05). Both low IGF-1 and high CRP levels had an almost linear relationship with the number of MetS components (p=0.029 and p=0.020, respectively), suggesting a close relationship of both variables with the cardiovascular disease (CVD) risk involved. The correlation between high CRP and low total IGF-1 might indicate that an increase in CRP levels may well be a key factor for the reduction in IGF-1 concentrations. Both factors are related to an increase in risk for MetS and CVD and this finding might have clinical implications in preventing or treating MetS, DM, and CVD. Given the cross-sectional design of the study, this finding should be confirmed by larger prospective and, it is hoped, interventional studies.

Angiology, Vol. 57, No. 3, 303-311 (2006)
DOI: 10.1177/000331970605700306


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Tiffin, I. Okpechi, C. Perez-Iratxeta, M. A. Andrade-Navarro, and R. Ramesar Prioritization of candidate disease genes for metabolic syndrome by computational analysis of its defining phenotypes Physiol Genomics, September 17, 2008; 35(1): 55 - 64. [Abstract] [Full Text] [PDF]